Conference Call with Ipca Laboratories Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ipca Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Standalone Net total Income up 8% at Rs 1827.94 crore. Consolidated Net total Income up 15% at Rs 2381.16 crore. Indian formulations income up 11% at Rs 940.51 crore. Exports Income up 6% at Rs 762.90 crore. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.89% in Q2FY25 as against @ 20.86% in Q2FY24. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) . @1.9.10% in Q2FY25 as against@ 17.64 % in Q2FY24. Standalone Net Profit at Rs 244.12 crore (after exceptional items) up 51%. Consolidated Net Profit at Rs 229.48 crore (after exceptional items) up 58%. The Board has declared an interim dividend of Rs 2/- per share (200%). H1FY25 Financial Highlights: Standalone Net Total Income up 6% at Rs 3409.19 crore. Consolidated Net Total Income up 21% at Rs 4494.40 crore. Indian formulations income up 11 % at Rs 1813.88 crore. Exports Income up 1 % at Rs 1353.76 crore. Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.59 % in FY25 as against @ 20.04 % in FY24. Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 18.83% in FY25 as against @ 18.05% in FY24. Standalone Net Profit at Rs 448.25 crore (after exceptional items) up 36%. Consolidated Net Profit at Rs 421.72 crore (after exceptional items) up 37%. Result PDF